The global lymphoma treatment market size was valued at USD 11.7 billion in 2018 and is anticipated to grow at a CAGR of 9.5% over the forecast period. The growing uptake of premium-priced products such as immune checkpoint inhibitors, Keytruda, and Opdivo is driving the market.
Also, the launch of several novel therapies and label extensions of commercialized products are expected to boost the growth. For instance, in 2018, the U.S. FDA approved Adcetris for use in patients with an advanced stage of classical Hodgkin lymphoma in combination with chemotherapy.
According to Leukemia & Lymphoma Society, in 2019, 82,310 new cases of lymphoma and 8,110 & 74,200 cases of Hodgkin & Non-Hodgkin Lymphoma (NHL), respectively, are expected to be diagnosed in the U.S. Moreover, it is estimated that there are 874,730 people in remission or are living with lymphoma in the U.S. The 5-year survival rate of patients with Hodgkin Lymphoma (HL) has more than doubled. The survival rate is 93.9% for patients with HL aged 45 and below at diagnosis. It has been estimated that in 2019, about 20,970 people in the U.S. are likely to die from lymphoma.
Large pharmaceutical companies operating in the oncology space are adopting strategies such as collaborations and acquisitions to further strengthen their position in the lymphoma treatments market. In 2015, cancer therapeutics witnessed a substantial number of collaborations, reflecting players growing interest in this domain. Numerous research institutes and organizations globally are collaborating to develop novel therapies for treatments of lymphoma.
For instance, in 2015, Amgen, Inc. collaborated with Merck & Co., Inc. to support a cancer immunotherapy phase 1b/3 study, investigating Keytruda in combination with Blincyto in individuals with Diffuse Large B-cell Lymphoma (DLBCL), which is the most common type of NHL. This study is a multicenter, open-label, randomized trial to evaluate efficacy and safety in patients with DLBCL.
Based on type, the market is categorized into Hodgkin and non-Hodgkin lymphomas. NHL held the largest share in 2018 owing to the presence of blockbuster drugs such as Revlimid, Rituxan, and Imbruvica, which are some of the biggest revenue-generating oncology drugs.
Hodgkin lymphoma is expected to witness the fastest growth during the forecast period due to the label extension of existing drugs and the launch of new therapies for relapsed or refractory HL. Also, the presence of a strong product pipeline along with the expected commercialization of these products is one of the factors expected to drive growth.
Based on drugs, the market for lymphoma treatments is segmented into Adcetris, Opdivo, Rituxan, Imbruvica, Keytruda, Revlimid, and others. Revlimid held the largest share in 2018 and is expected to witness significant growth during the forecast period. Revlimid sales are being driven by an increase in the duration of cancer treatments. Rituxan/MabThera held the second-largest share in 2018 owing to the increasing use of this product in multiple indications along with a high prescription rate in major markets such as the U.S. and Europe.
However, Rituxan/MabThera sales declined in Europe in 2018, which was driven by competition from biosimilars in the region. The first biosimilar version of Rituxan/MabThera is expected to enter the U.S. market in the second half of 2019. Thus, Rituxan/MabThera is likely to witness a decline in sales during the forecast period in the U.S.
North America held the largest share in 2018 and is expected to dominate during the forecast period. This can be attributed to the presence of key players, availability of novel drugs, wee-established healthcare infrastructure, and high R&D expenditure.
Asia Pacific is expected to witness the fastest growth during the forecast period with a CAGR of nearly 11% owing to a rise in healthcare expenditure, high unmet clinical needs, an increase in awareness about treatment options, and availability of effective treatment in emerging countries such as China & South Korea.
Some of the key players in the lymphoma treatment market are Bristol-Myers Squibb Company; Celgene Corporation; Merck & Co., Inc.; F. Hoffmann-La Roche Ltd.; Seattle Genetics, Inc.; Takeda Pharmaceutical Company Ltd.; Johnson & Johnson; Eli Lilly and Company; and Abbott Laboratories.
Key players are adopting various strategies such as mergers & acquisitions to increase their market share. Furthermore, players are collaborating to launch their products in different regions to further strengthen their position in the market. For instance, Seattle Genetics collaborated with Takeda Pharmaceuticals to commercialize its product Adcetris in key regions other than North America.
Attribute |
Details |
The base year for estimation |
2018 |
Actual estimates/Historical data |
2015 - 2017 |
Forecast period |
2019 - 2026 |
Market representation |
Revenue in USD Million & CAGR from 2019 to 2026 |
Regional scope |
North America, Europe, Asia Pacific, Latin America, MEA |
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors, and trends |
Country scope |
U.S., Canada, U.K., Germany, France, Italy, Spain, Japan, China, South Korea, Australia, Brazil, Mexico, Argentina, South Africa, UAE |
15% free customization scope (equivalent to 5 analysts working days) |
If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization |
This report forecasts revenue growth at global, regional, & country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2015 to 2026. For this study, Grand View Research has segmented the global lymphoma treatment market report based on type, drug, and region:
Type Outlook (Revenue, USD Million, 2015 - 2026)
Hodgkin Lymphoma
Non-Hodgkin Lymphoma
Drug Outlook (Revenue, USD Million, 2015 - 2026)
Adcetris
Rituxan/MabThera
Imbruvica
Keytruda
Revlimid
Others
Regional Outlook (Revenue, USD Million, 2015 - 2026)
North America
The U.S.
Canada
Europe
U.K.
Germany
France
Italy
Spain
Asia Pacific
Japan
China
South Korea
Australia
Latin America
Brazil
Mexico
Argentina
MEA
South Africa
UAE
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
ISO Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."
Multiple therapeutic regimens are being followed across the globe in attempts to come up with a reliable treatment for Covid-19. One line of treatment includes the use of hydroxychloroquine, while a second treatment line focuses to use antiviral drugs used in the disease management of HIV. Both these approaches have surged demand from advanced antivirals and antimalarial drugs. This impacts the drug manufacturers as an off label indication for these drug classes has to be worked upon. At the moment, the WHO has not prescribed any of these approaches, neither they have commented if one is better than the other. The report will account for Covid19 as a key market contributor.
We value your investment and offer free customization with every report to fulfil your exact research needs.